サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1422237

組換えタンパク質の世界市場：製品別、用途別（創薬開発、研究開発、バイオ医薬品生産）、宿主細胞別、エンドユーザー別、地域別-2028年までの予測

Recombinant Proteins Market by Product, Application (Drug Discovery & Development, Research, Biopharma Production) & Region - Global Forecast to 2028
出版日: | 発行: MarketsandMarkets | ページ情報: 英文 408 Pages | 納期: 即納可能 即納可能とは

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.76円
組換えタンパク質の世界市場：製品別、用途別（創薬開発、研究開発、バイオ医薬品生産）、宿主細胞別、エンドユーザー別、地域別-2028年までの予測
出版日: 2024年02月05日
発行: MarketsandMarkets
ページ情報: 英文 408 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要

世界の組換えタンパク質市場規模は、2023年の22億米ドルから2028年には32億米ドルに達すると予測され、予測期間中のCAGRは7.2%になるとみられています。

特許切れによる生物製剤とバイオシミラーの需要増加、慢性疾患の蔓延、ライフサイエンス研究開発への政府支援の増加、個別化医療への嗜好の高まりなどの要因があります。

調査範囲
調査対象年 2021年～2028年
基準年 2022年
予測期間 2023年～2028年
検討単位 金額（10億米ドル）
セグメント別 製品別、用途別、宿主細胞別、エンドユーザー別
対象地域 北米、欧州、アジア太平洋、ラテンアメリカ、中東・アフリカ

製品別では、世界の組換えタンパク質は、成長因子とケモカイン、キナーゼタンパク質、膜タンパク質、免疫応答タンパク質、構造タンパク質、制御タンパク質、組み換え代謝酵素、接着分子と受容体、およびその他の組み換えタンパク質にセグメント化されます。成長因子とケモカインのセグメントはさらにインターフェロン、インターロイキン、その他の成長因子とケモカインにセグメント化されます。成長因子・ケモカインセグメントは、細胞培養、タンパク質発現、細胞応答の調節への応用により、著しいCAGRで成長すると予測されています。

用途別に見ると、組換えタンパク質市場は、創薬・開発、バイオ医薬品生産、研究開発、診断、その他の用途に区分されます。2022年には、創薬・開発分野が組換えタンパク質市場で最大のシェアを占めました。同セグメントは、バイオ医薬品の開発や潜在的な創薬ターゲットの機能解明における組み換えタンパク質の応用により、市場で最大のシェアを占めています。

組換えタンパク質市場は、地域別では北米、欧州、アジア太平洋、ラテンアメリカ、中東・アフリカに区分されます。アジア太平洋は、予測期間中に大きなCAGRで成長すると予想されています。同地域の成長の主な原動力は、タンパク質ベースの医薬品に対する需要の増加、組換えタンパク質生産に対する政府資金の増加、バイオテクノロジーベースの医薬品開発です。

当レポートでは、世界の組換えタンパク質市場について調査し、製品別、用途別、宿主細胞別、エンドユーザー別、地域別動向、および市場に参入する企業のプロファイルなどをまとめています。

目次

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要考察

第5章 市場概要

  • イントロダクション
  • 市場力学
  • 顧客のビジネスに影響を与える動向/混乱
  • 価格分析
  • 技術分析
  • バリューチェーン分析
  • 生態系市場/マップ
  • 規制分析
  • ポーターのファイブフォース分析
  • 特許分析
  • 主要な会議とイベント
  • 主要な利害関係者と購入基準

第6章 組換えタンパク質市場、製品別

  • イントロダクション
  • 成長因子とケモカイン
  • 免疫応答タンパク質
  • 構造タンパク質
  • 膜タンパク質
  • キナーゼタンパク質
  • 調節タンパク質
  • 組換え代謝酵素
  • 接着分子と受容体
  • その他

第7章 組換えタンパク質市場、用途別

  • イントロダクション
  • 創薬と開発
  • 研究
  • バイオ医薬品生産
  • 診断
  • その他

第8章 組換えタンパク質市場、宿主細胞別

  • イントロダクション
  • 哺乳類系
  • 昆虫細胞
  • 酵母と菌類
  • 細菌細胞
  • その他

第9章 組換えタンパク質市場、エンドユーザー別

  • イントロダクション
  • 製薬会社およびバイオ医薬品会社
  • バイオテクノロジー企業
  • 学術研究機関
  • CRO
  • その他

第10章 組換えタンパク質市場、地域別

  • イントロダクション
  • 北米
  • 欧州
  • アジア太平洋
  • ラテンアメリカ
  • 中東
  • アフリカ

第11章 競合情勢

  • イントロダクション
  • 主要参入企業の戦略
  • 収益シェア分析
  • 市場シェア分析
  • 企業評価マトリックス
  • スタートアップ/中小企業の評価マトリックス
  • 競合シナリオ

第12章 企業プロファイル

  • 主要参入企業
    • BIO-TECHNE
    • THERMO FISHER SCIENTIFIC INC.
    • MERCK KGAA
    • ABCAM PLC
    • ABNOVA CORPORATION
    • BIOLEGEND, INC
    • BIO-RAD LABORATORIES, INC.
    • BPS BIOSCIENCE, INC.
    • ENZO LIFE SCIENCES, INC.（SUBSIDIARY OF ENZO BIOCHEM, INC.）
    • GENSCRIPT
    • MILTENYI BIOTEC B.V. & CO. KG
    • PROTEINTECH GROUP, INC.
    • SINO BIOLOGICAL, INC.
  • その他の企業
    • ACROBIOSYSTEMS GROUP
    • AVIVA SYSTEMS BIOLOGY CORPORATION
    • SARTORIUS CELLGENIX GMBH
    • ICOSAGEN
    • NEUROMICS
    • PROSPEC-TANY TECHNOGENE LTD.
    • PROTEOGENIX S.A.S
    • RAYBIOTECH, INC.
    • LAURUS BIO
    • STEMCELL TECHNOLOGIES
    • STRESSMARQ BIOSCIENCES INC.
    • UNITED STATES BIOLOGICAL

第13章 付録

目次
Product Code: BT 7839

The global recombinant proteins market size is projected to reach USD 3.2 billion by 2028 from USD 2.2 billion in 2023, at a CAGR of 7.2% during the forecast period. Factors such as rising demand for biologics & biosimilars due to patent expiry, increasing prevalence of chronic diseases, increased government support for life sciences research & development and growing preference for personalized medicine..

Scope of the Report
Years Considered for the Study2021-2028
Base Year2022
Forecast Period2023-2028
Units ConsideredValue (USD) Billion
SegmentsBy Product, By Application, By Host cell, By End User
Regions coveredNorth America, Europe, Asia Pacific, Latin America, Middle East and Africa

"The growth factors and chemokines segment segment held the dominant share in the recombinant proteins market"

Based on product, the global recombinant proteins market is segmented into growth factors and chemokines, kinase proteins, membrane proteins, immune response proteins, structural proteins, regulatory proteins, recombinant metabolic enzymes, adhesion molecules and receptors, and other recombinant proteins. The growth factors and chemokines segment is further segmented into interferons, interleukins and other growth factor & chemokines. The growth factors and chemokines segment is anticipated to grow at significant CAGR due to their application in cell culture, protein expression, and modulation of cellular responses.

"Drug discovery & development segment accounted for the largest share of the application segment in 2022."

Based on application, the recombinant proteins market is segmented into, drug discovery and development, biopharmaceutical production, research, diagnostics, and other applications. In 2022, the drug discovery and development segment accounted for the largest share of the recombinant proteins market. The segment held the largest share in the market due to application of recombinant proteins in developing biopharmaceuticals and understanding the functions of potential drug targets.

"Asia Pacific region is likely to grow at a faster pace in the recombinant proteins market."

The recombinant proteins market region is segmented into North America, Europe, Asia Pacific, Latin America, Middle East and the Africa. Asia Pacific region is anticipated to grow at a significant CAGR during the forecast period. The growth of the region is majorly driven by increasing demand for protein based drugs, rising government funding for recombinant proteins production and development of biotechnology-based drugs.

The primary interviews conducted for this report can be categorized as follows:

  • By Respondent: Supply Side- 70%, and Demand Side - 30%
  • By Designation (Supply Side): Managers - 45%, CXOs & Directors - 30%, Executives- 25%
  • By Region: North America: 40%, Europe: 25%, Asia Pacific: 20%, Latin America: 10%, and the Middle East and Africa: 5%

List of Companies Profiled in the Report:

  • Bio-Techne (US)
  • Thermo Fisher Scientific Inc. (US)
  • Merck KGaA (Germany)
  • Abcam plc (UK)
  • Abnova Corporation (Taiwan)
  • Biolegend Inc (US)
  • Bio-Rad Laboratories Inc. (US)
  • BPS Bioscienc Inc (US)
  • Enzo Biochem, Inc. (US)
  • GenScript (China)
  • Miltenyi Biotec B.V. & Co. KG (Germany)
  • Proteintech Group, Inc. (US)
  • Sino Biological Inc. (China)
  • ACROBiosystems Group (US)
  • Aviva Systems Biology Corporation (US)
  • Sartorius CellGenix GmbH (Germany)
  • Icosagen (Estonia)
  • Neuromics (US)
  • ProSpec-Tany Technogene Ltd. (Israel)
  • ProteoGenix S.A.S (France)
  • RayBiotech Inc (US)
  • Lauraus Bio (India)
  • Stemcell Technologies (Canada)
  • StressMarq Biosciences Inc. (Canada)
  • United States Biological (US)

Research Coverage:

This report provides a detailed picture of the recombinant proteins market. It aims at estimating the size and future growth potential of the market across different segments such as the product, application, end-user and region. The report also includes an in-depth competitive analysis of the key market players along with their company profiles recent developments and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall recombinant proteins market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

  • Analysis of key drivers (rising incidence of chronic diseases, unleashing innovation in biologics and biosimilars with patent expiry, increasing government support for R&D in life sciences, growing preference for personalized medicine), restraints (high production costs, stringent regulatory approval processes), opportunities (advancements in gene editing technologies, high growth potential of emerging markets, emergence of novel expression systems) and challenges (challenges associated with delivery systems) are influencing the growth of recombinant proteins market.
  • Product Development/Innovation: Detailed insights on newly launched products of the recombinant proteins market.
  • Market Development: Comprehensive information about lucrative markets - the report analyses the recombinant proteins market across varied regions.
  • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the recombinant proteins market.
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players include Bio-Techne (US), Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Abcam plc (UK), Abnova Corporation (Taiwan), Biolegend Inc (US), Bio-Rad Laboratories Inc. (US), BPS Bioscienc Inc (US), Enzo Biochem Inc. (US) and GenScript (China).

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS AND EXCLUSIONS
  • 1.3 MARKET SCOPE
    • 1.3.1 MARKETS COVERED
    • 1.3.2 YEARS CONSIDERED
    • 1.3.3 CURRENCY CONSIDERED
  • 1.4 RESEARCH LIMITATIONS
  • 1.5 STAKEHOLDERS
  • 1.6 SUMMARY OF CHANGES
  • 1.7 RECESSION IMPACT

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • FIGURE 1 RESEARCH DESIGN
    • 2.1.1 SECONDARY DATA
    • 2.1.2 PRIMARY DATA
    • FIGURE 2 RECOMBINANT PROTEINS MARKET: BREAKDOWN OF PRIMARIES
  • 2.2 MARKET SIZE ESTIMATION
    • FIGURE 3 MARKET SIZE ESTIMATION: SUPPLY SIDE ANALYSIS (2022)
    • FIGURE 4 MARKET SIZE ESTIMATION: APPROACH 1 (REVENUE SHARE ANALYSIS), 2022
    • FIGURE 5 ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC INC.: REVENUE SHARE ANALYSIS (2022)
    • 2.2.1 INSIGHTS FROM PRIMARIES
    • FIGURE 6 MARKET VALIDATION FROM PRIMARY EXPERTS
    • 2.2.2 SEGMENT ASSESSMENT (BY PRODUCT, APPLICATION, HOST CELL, AND END USER)
    • FIGURE 7 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
  • 2.3 GROWTH RATE ASSUMPTIONS
    • FIGURE 8 RECOMBINANT PROTEINS MARKET: CAGR PROJECTIONS (2023-2028)
    • FIGURE 9 RECOMBINANT PROTEINS MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, CHALLENGES, AND OPPORTUNITIES
  • 2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
    • FIGURE 10 DATA TRIANGULATION METHODOLOGY
  • 2.5 STUDY ASSUMPTIONS
  • 2.6 RISK ANALYSIS
  • 2.7 RECESSION IMPACT ANALYSIS
    • TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2024-2028 (% GROWTH)
    • TABLE 2 US HEALTH EXPENDITURE, 2019-2022 (USD MILLION)
    • TABLE 3 US HEALTH EXPENDITURE, 2023-2027 (USD MILLION)

3 EXECUTIVE SUMMARY

    • FIGURE 11 RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION)
    • FIGURE 12 RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION)
    • FIGURE 13 RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2023 VS. 2028 (USD MILLION)
    • FIGURE 14 RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY TYPE, 2023 VS. 2028 (USD MILLION)
    • FIGURE 15 RECOMBINANT PROTEINS MARKET, BY HOST CELL, 2023 VS. 2028 (USD MILLION)
    • FIGURE 16 RECOMBINANT PROTEINS MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
    • FIGURE 17 GEOGRAPHICAL SNAPSHOT OF RECOMBINANT PROTEINS MARKET

4 PREMIUM INSIGHTS

  • 4.1 RECOMBINANT PROTEINS MARKET OVERVIEW
    • FIGURE 18 INCREASING GOVERNMENT SUPPORT FOR R&D IN LIFE SCIENCES TO DRIVE MARKET
  • 4.2 NORTH AMERICA: RECOMBINANT PROTEINS MARKET, BY PRODUCT (2022)
    • FIGURE 19 GROWTH FACTORS & CHEMOKINES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2022
  • 4.3 RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2023 VS. 2028
    • FIGURE 20 GROWTH FACTORS & CHEMOKINES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
  • 4.4 RECOMBINANT PROTEINS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
    • FIGURE 21 ASIA PACIFIC COUNTRIES TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 22 RECOMBINANT PROTEINS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • TABLE 4 RECOMBINANT PROTEINS MARKET: IMPACT ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • 5.2.1 DRIVERS
      • 5.2.1.1 Rising incidence of chronic diseases
    • FIGURE 23 NUMBER OF CANCER CASES IN US (2017 - 2022)
      • 5.2.1.2 Increasing demand for biologics and biosimilars due to patent expiry
      • 5.2.1.3 Increasing government support for R&D in life sciences
    • TABLE 5 GOVERNMENT FUNDING FOR LIFE SCIENCE RESEARCH (2022)
      • 5.2.1.4 Growing preference for personalized medicine
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 High production costs
      • 5.2.2.2 Stringent regulatory approval processes
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Advancements in gene editing technologies
      • 5.2.3.2 High growth potential of emerging markets
      • 5.2.3.3 Emergence of novel expression systems
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Challenges associated with delivery systems
  • 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
    • FIGURE 24 REVENUE SHIFTS AND NEW REVENUE POCKETS FOR RECOMBINANT PROTEIN MANUFACTURERS
  • 5.4 PRICING ANALYSIS
    • 5.4.1 AVERAGE SELLING PRICE OF PRODUCTS, BY KEY PLAYERS
    • TABLE 6 RECOMBINANT PROTEIN PRODUCTS
    • 5.4.2 AVERAGE SELLING PRICE TREND OF RECOMBINANT PROTEINS
  • 5.5 TECHNOLOGY ANALYSIS
  • 5.6 VALUE CHAIN ANALYSIS
    • FIGURE 25 VALUE CHAIN ANALYSIS: MANUFACTURING & ASSEMBLY PHASE CONTRIBUTES MAXIMUM VALUE TO VALUE CHAIN OF RECOMBINANT PROTEINS
  • 5.7 ECOSYSTEM MARKET/MAP
    • FIGURE 26 ECOSYSTEM MARKET/MAP
    • TABLE 7 RECOMBINANT PROTEINS MARKET: ROLE IN ECOSYSTEM:
  • 5.8 REGULATORY ANALYSIS
    • TABLE 8 KEY REGULATORY AGENCIES
    • 5.8.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 9 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 10 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 11 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 12 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 13 MIDDLE EAST: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 14 AFRICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.9 PORTER'S FIVE FORCES ANALYSIS
    • TABLE 15 RECOMBINANT PROTEINS MARKET: PORTER'S FIVE FORCES ANALYSIS
    • 5.9.1 THREAT OF NEW ENTRANTS
    • 5.9.2 THREAT OF SUBSTITUTES
    • 5.9.3 BARGAINING POWER OF SUPPLIERS
    • 5.9.4 BARGAINING POWER OF BUYERS
    • 5.9.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.10 PATENT ANALYSIS
    • FIGURE 27 PATENT APPLICATIONS FOR RECOMBINANT PROTEINS, DECEMBER 2013-DECEMBER 2023
    • TABLE 16 RECOMBINANT PROTEINS MARKET: INDICATIVE LIST OF PATENTS
  • 5.11 KEY CONFERENCES AND EVENTS
    • TABLE 17 DETAILED LIST OF KEY CONFERENCES AND EVENTS (2023-2024)
  • 5.12 KEY STAKEHOLDERS AND BUYING CRITERIA
    • 5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • FIGURE 28 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR RECOMBINANT PROTEINS
    • 5.12.2 BUYING CRITERIA FOR RECOMBINANT PROTEINS
    • FIGURE 29 KEY BUYING CRITERIA FOR END USERS

6 RECOMBINANT PROTEINS MARKET, BY PRODUCT

  • 6.1 INTRODUCTION
    • TABLE 18 RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
  • 6.2 GROWTH FACTORS & CHEMOKINES
    • TABLE 19 RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 20 RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 21 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 22 EUROPE: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 23 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 24 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 25 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, COUNTRY, 2021-2028 (USD MILLION)
    • 6.2.1 INTERFERONS (IFNS)
      • 6.2.1.1 Ability to regulate critical cellular processes across research applications to propel market
    • TABLE 26 RECOMBINANT PROTEINS MARKET FOR INTERFERONS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 27 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR INTERFERONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 28 EUROPE: RECOMBINANT PROTEINS MARKET FOR INTERFERONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 29 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR INTERFERONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 30 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR INTERFERONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 31 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR INTERFERONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • 6.2.2 INTERLEUKINS (ILS)
      • 6.2.2.1 Rising focus on personalized therapeutics to drive market
    • TABLE 32 RECOMBINANT PROTEINS MARKET FOR INTERLEUKINS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 33 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR INTERLEUKINS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 34 EUROPE: RECOMBINANT PROTEINS MARKET FOR INTERLEUKINS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 35 ASAI PACIFIC: RECOMBINANT PROTEINS MARKET FOR INTERLEUKINS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 36 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR INTERLEUKINS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 37 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR INTERLEUKINS, BY COUNTRY, 2021-2028 (USD MILLION)
    • 6.2.3 OTHER GROWTH FACTORS & CHEMOKINES
    • TABLE 38 RECOMBINANT PROTEINS MARKET FOR OTHER GROWTH FACTORS & CHEMOKINES, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 39 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR OTHER GROWTH FACTORS & CHEMOKINES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 40 EUROPE: RECOMBINANT PROTEINS MARKET FOR OTHER GROWTH FACTORS & CHEMOKINES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 41 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR OTHER GROWTH FACTORS & CHEMOKINES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 42 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR OTHER GROWTH FACTORS & CHEMOKINES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 43 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR OTHER GROWTH FACTORS & CHEMOKINES, BY COUNTRY, 2021-2028 (USD MILLION)
  • 6.3 IMMUNE RESPONSE PROTEINS
    • 6.3.1 HIGH UTILIZATION OF IMMUNE CHECKPOINT PROTEINS IN CANCER IMMUNOTHERAPY TO PROPEL MARKET
    • TABLE 44 RECOMBINANT PROTEINS MARKET FOR IMMUNE RESPONSE PROTEINS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 45 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR IMMUNE RESPONSE PROTEINS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 46 EUROPE: RECOMBINANT PROTEINS MARKET FOR IMMUNE RESPONSE PROTEINS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 47 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR IMMUNE RESPONSE PROTEINS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 48 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR IMMUNE RESPONSE PROTEINS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 49 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR IMMUNE RESPONSE PROTEINS, BY COUNTRY, 2021-2028 (USD MILLION)
  • 6.4 STRUCTURAL PROTEINS
    • 6.4.1 ATTACHMENT FACTORS IN CELL CULTURE APPLICATIONS TO DRIVE MARKET
    • TABLE 50 RECOMBINANT PROTEINS MARKET FOR STRUCTURAL PROTEINS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 51 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR STRUCTURAL PROTEINS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 52 EUROPE: RECOMBINANT PROTEINS MARKET FOR STRUCTURAL PROTEINS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 53 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR STRUCTURAL PROTEINS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 54 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR STRUCTURAL PROTEINS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 55 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR STRUCTURAL PROTEINS, BY COUNTRY, 2021-2028 (USD MILLION)
  • 6.5 MEMBRANE PROTEINS
    • 6.5.1 ESSENTIAL PROCESS REGULATION OF STRUCTURAL CELLS TO SUPPORT MARKET GROWTH
    • TABLE 56 RECOMBINANT PROTEINS MARKET FOR MEMBRANE PROTEINS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 57 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR MEMBRANE PROTEINS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 58 EUROPE: RECOMBINANT PROTEINS MARKET FOR MEMBRANE PROTEINS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 59 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR MEMBRANE PROTEINS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 60 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR MEMBRANE PROTEINS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 61 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR MEMBRANE PROTEINS, BY COUNTRY, 2021-2028 (USD MILLION)
  • 6.6 KINASE PROTEINS
    • 6.6.1 ACTIVE METABOLIZATION OF LIPIDS AND NUCLEOTIDES TO DRIVE MARKET
    • TABLE 62 RECOMBINANT PROTEINS MARKET FOR KINASE PROTEINS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 63 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR KINASE PROTEINS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 64 EUROPE: RECOMBINANT PROTEINS MARKET FOR KINASE PROTEINS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 65 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR KINASE PROTEINS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 66 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR KINASE PROTEINS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 67 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR KINASE PROTEINS, BY COUNTRY, 2021-2028 (USD MILLION)
  • 6.7 REGULATORY PROTEINS
    • 6.7.1 ABILITY TO MODULATE CELLULAR PROCESSES TO DRIVE MARKET
    • TABLE 68 RECOMBINANT PROTEINS MARKET FOR REGULATORY PROTEINS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 69 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR REGULATORY PROTEINS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 70 RECOMBINANT PROTEINS MARKET FOR REGULATORY PROTEINS IN EUROPE, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 71 EUROPE: RECOMBINANT PROTEINS MARKET FOR REGULATORY PROTEINS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 72 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR REGULATORY PROTEINS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 73 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR REGULATORY PROTEINS, BY COUNTRY, 2021-2028 (USD MILLION)
  • 6.8 RECOMBINANT METABOLIC ENZYMES
    • 6.8.1 HIGH ADOPTION IN BIOTECHNOLOGICAL APPLICATIONS FOR THERAPEUTIC DEVELOPMENT TO BOOST DEMAND
    • TABLE 74 RECOMBINANT PROTEINS MARKET FOR RECOMBINANT METABOLIC ENZYMES, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 75 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR RECOMBINANT METABOLIC ENZYMES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 76 EUROPE: RECOMBINANT PROTEINS MARKET FOR RECOMBINANT METABOLIC ENZYMES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 77 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR RECOMBINANT METABOLIC ENZYMES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 78 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR RECOMBINANT METABOLIC ENZYMES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 79 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR RECOMBINANT METABOLIC ENZYMES, BY COUNTRY, 2021-2028 (USD MILLION)
  • 6.9 ADHESION MOLECULES & RECEPTORS
    • 6.9.1 ENHANCED FACILITATION OF EXTRACELLULAR MATRIX INTERACTIONS TO SUPPORT MARKET GROWTH
    • TABLE 80 RECOMBINANT PROTEINS MARKET FOR ADHESION MOLECULES & RECEPTORS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 81 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR ADHESION MOLECULES & RECEPTORS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 82 EUROPE: RECOMBINANT PROTEINS MARKET FOR ADHESION MOLECULES & RECEPTORS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 83 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR ADHESION MOLECULES & RECEPTORS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 84 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR ADHESION MOLECULES & RECEPTORS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 85 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR ADHESION MOLECULES & RECEPTORS, BY COUNTRY, 2021-2028 (USD MILLION)
  • 6.10 OTHER RECOMBINANT PROTEINS
    • TABLE 86 RECOMBINANT PROTEINS MARKET FOR OTHER RECOMBINANT PROTEINS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 87 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR OTHER RECOMBINANT PROTEINS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 88 EUROPE: RECOMBINANT PROTEINS MARKET FOR OTHER RECOMBINANT PROTEINS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 89 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR OTHER RECOMBINANT PROTEINS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 90 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR OTHER RECOMBINANT PROTEINS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 91 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR OTHER RECOMBINANT PROTEINS, BY COUNTRY, 2021-2028 (USD MILLION)

7 RECOMBINANT PROTEINS MARKET, BY APPLICATION

  • 7.1 INTRODUCTION
    • TABLE 92 RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • 7.2 DRUG DISCOVERY & DEVELOPMENT
    • TABLE 93 RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 94 RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 95 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 96 EUROPE: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 97 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 98 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 99 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2021-2028 (USD MILLION)
    • 7.2.1 BIOLOGICS
      • 7.2.1.1 High adoption in autoimmune disease & cancer treatment to propel market
    • TABLE 100 RECOMBINANT PROTEINS MARKET: KEY BIOLOGICS AND INDICATIONS
    • TABLE 101 RECOMBINANT PROTEINS MARKET FOR BIOLOGICS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 102 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR BIOLOGICS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 103 EUROPE: RECOMBINANT PROTEINS MARKET FOR BIOLOGICS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 104 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR BIOLOGICS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 105 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR BIOLOGICS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 106 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR BIOLOGICS, BY COUNTRY, 2021-2028 (USD MILLION)
    • 7.2.2 VACCINES
      • 7.2.2.1 Rising incidence of infectious diseases to boost demand
    • TABLE 107 RECOMBINANT PROTEINS MARKET FOR VACCINES, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 108 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR VACCINES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 109 EUROPE: RECOMBINANT PROTEINS MARKET FOR VACCINES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 110 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR VACCINES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 111 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR VACCINES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 112 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR VACCINES, BY COUNTRY, 2021-2028 (USD MILLION)
    • 7.2.3 CELL & GENE THERAPY
      • 7.2.3.1 Growing focus on CAR-T therapies to propel market
    • TABLE 113 RECOMBINANT PROTEINS MARKET FOR CELL & GENE THERAPY, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 114 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 115 EUROPE: RECOMBINANT PROTEINS MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 116 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 117 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 118 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2021-2028 (USD MILLION)
  • 7.3 RESEARCH
    • TABLE 119 RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 120 RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY REGION, 2021-2028 USD MILLION)
    • TABLE 121 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 122 EUROPE: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 123 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 124 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 125 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY COUNTRY, 2021-2028 (USD MILLION)
    • 7.3.1 ACADEMIC RESEARCH
      • 7.3.1.1 Wide application in molecular & gene expression studies to propel market
    • TABLE 126 RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH STUDIES, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 127 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 128 EUROPE: RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH STUDIES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 129 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 130 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 131 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH, BY COUNTRY, 2021-2028 (USD MILLION)
    • 7.3.2 BIOTECHNOLOGY RESEARCH
      • 7.3.2.1 Growing focus on bioengineering and genomics to fuel market
    • TABLE 132 RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY RESEARCH, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 133 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY RESEARCH, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 134 EUROPE: RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY RESEARCH, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 135 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY RESEARCH, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 136 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY RESEARCH, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 137 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY RESEARCH, BY COUNTRY, 2021-2028 (USD MILLION)
  • 7.4 BIOPHARMACEUTICAL PRODUCTION
    • 7.4.1 INCREASING DEVELOPMENT OF PROTEIN-BASED DRUGS TO SUPPORT MARKET GROWTH
    • TABLE 138 RECOMBINANT PROTEINS MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 139 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 140 EUROPE: RECOMBINANT PROTEINS MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 141 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 142 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 143 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY COUNTRY, 2021-2028 (USD MILLION)
  • 7.5 DIAGNOSTICS
    • 7.5.1 GROWING FOCUS ON EARLY DISEASE DETECTION TO DRIVE MARKET
    • TABLE 144 RECOMBINANT PROTEINS MARKET FOR DIAGNOSTICS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 145 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 146 EUROPE: RECOMBINANT PROTEINS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 147 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 148 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 149 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2021-2028 (USD MILLION)
  • 7.6 OTHER APPLICATIONS
    • TABLE 150 RECOMBINANT PROTEINS MARKET FOR OTHER APPLICATIONS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 151 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 152 EUROPE: RECOMBINANT PROTEINS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 153 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 154 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 155 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)

8 RECOMBINANT PROTEINS MARKET, BY HOST CELL

  • 8.1 INTRODUCTION
    • TABLE 156 RECOMBINANT PROTEINS MARKET, BY HOST CELL, 2021-2028 (USD MILLION)
  • 8.2 MAMMALIAN SYSTEMS
    • 8.2.1 HIGH UPTAKE IN BIOTECHNOLOGY APPLICATIONS TO PROPEL MARKET
    • TABLE 157 RECOMBINANT PROTEINS MARKET FOR MAMMALIAN SYSTEMS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 158 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR MAMMALIAN SYSTEMS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 159 EUROPE: RECOMBINANT PROTEINS MARKET FOR MAMMALIAN SYSTEMS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 160 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR MAMMALIAN SYSTEMS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 161 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR MAMMALIAN SYSTEMS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 162 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR MAMMALIAN SYSTEMS, BY COUNTRY, 2021-2028 (USD MILLION)
  • 8.3 INSECT CELLS
    • 8.3.1 COST-EFFICIENT AND HIGH-YIELD CHARACTERISTICS TO DRIVE MARKET
    • TABLE 163 RECOMBINANT PROTEINS MARKET FOR INSECT CELLS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 164 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR INSECT CELLS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 165 EUROPE: RECOMBINANT PROTEINS MARKET FOR INSECT CELLS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 166 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR INSECT CELLS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 167 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR INSECT CELLS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 168 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR INSECT CELLS, BY COUNTRY, 2021-2028 (USD MILLION)
  • 8.4 YEAST & FUNGI
    • 8.4.1 NEW APPLICATIONS IN VACCINE DEVELOPMENT AND DIABETES TREATMENT TO BOOST DEMAND
    • TABLE 169 RECOMBINANT PROTEINS MARKET FOR YEAST & FUNGI, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 170 RECOMBINANT PROTEINS MARKET FOR YEAST & FUNGI, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 171 RECOMBINANT PROTEINS MARKET FOR YEAST & FUNGI, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 172 RECOMBINANT PROTEINS MARKET FOR YEAST & FUNGI, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 173 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR YEAST & FUNGI, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 174 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR YEAST & FUNGI, BY COUNTRY, 2021-2028 (USD MILLION)
  • 8.5 BACTERIAL CELLS
    • 8.5.1 SIMPLIFIED GENETIC MANIPULATION AND SCALABILITY ADVANTAGES TO DRIVE MARKET
    • TABLE 175 RECOMBINANT PROTEINS MARKET FOR BACTERIAL CELLS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 176 RECOMBINANT PROTEINS MARKET FOR BACTERIAL CELLS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 177 RECOMBINANT PROTEINS MARKET FOR BACTERIAL CELLS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 178 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR BACTERIAL CELLS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 179 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR BACTERIAL CELLS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 180 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR BACTERIAL CELLS, BY COUNTRY, 2021-2028 (USD MILLION)
  • 8.6 OTHER HOST CELLS
    • TABLE 181 RECOMBINANT PROTEINS MARKET FOR OTHER HOST CELLS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 182 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR OTHER HOST CELLS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 183 EUROPE: RECOMBINANT PROTEINS MARKET FOR OTHER HOST CELLS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 184 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR OTHER HOST CELLS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 185 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR OTHER HOST CELLS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 186 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR OTHER HOST CELLS, BY COUNTRY, 2021-2028 (USD MILLION)

9 RECOMBINANT PROTEINS MARKET, BY END USER

  • 9.1 INTRODUCTION
    • TABLE 187 RECOMBINANT PROTEINS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 9.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES
    • 9.2.1 RISING DEVELOPMENT OF GENE THERAPIES AND VACCINES TO PROPEL MARKET
    • TABLE 188 RECOMBINANT PROTEINS MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 189 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 190 EUROPE: RECOMBINANT PROTEINS MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 191 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 192 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 193 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION)
  • 9.3 BIOTECHNOLOGY COMPANIES
    • 9.3.1 RISING NUMBER OF PROTEIN-BASED RESEARCH PROJECTS TO BOOST DEMAND
    • TABLE 194 RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY COMPANIES, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 195 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 196 EUROPE: RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 197 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 198 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 199 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION)
  • 9.4 ACADEMIC & RESEARCH INSTITUTES
    • 9.4.1 FAVORABLE GOVERNMENT INVESTMENTS TO PROPEL MARKET
    • TABLE 200 RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 201 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 202 EUROPE: RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 203 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 204 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 205 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2021-2028 (USD MILLION)
  • 9.5 CONTRACT RESEARCH ORGANIZATIONS
    • 9.5.1 RISING OUTSOURCING OF CLINICAL TRIAL SERVICES TO SUPPORT MARKET GROWTH
    • TABLE 206 RECOMBINANT PROTEINS MARKET FOR CROS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 207 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR CROS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 208 EUROPE: RECOMBINANT PROTEINS MARKET FOR CROS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 209 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR CROS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 210 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR CROS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 211 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR CROS, BY COUNTRY, 2021-2028 (USD MILLION)
  • 9.6 OTHER END USERS
    • TABLE 212 RECOMBINANT PROTEINS MARKET FOR OTHER END USERS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 213 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR OTHER END USERS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 214 EUROPE: RECOMBINANT PROTEINS MARKET FOR OTHER END USERS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 215 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR OTHER END USERS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 216 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR OTHER END USERS, BY COUNTRY, 2021-2028 USD MILLION)
    • TABLE 217 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR OTHER END USERS, BY COUNTRY, 2021-2028 (USD MILLION)

10 RECOMBINANT PROTEINS MARKET, BY REGION

  • 10.1 INTRODUCTION
    • TABLE 218 RECOMBINANT PROTEINS MARKET, BY REGION, 2021-2028 (USD MILLION)
  • 10.2 NORTH AMERICA
    • FIGURE 30 NORTH AMERICA: RECOMBINANT PROTEINS MARKET SNAPSHOT
    • TABLE 219 NORTH AMERICA: RECOMBINANT PROTEINS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 220 NORTH AMERICA: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 221 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 222 NORTH AMERICA: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 223 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 224 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 225 NORTH AMERICA: RECOMBINANT PROTEINS MARKET, BY HOST CELL, 2021-2028 USD MILLION)
    • TABLE 226 NORTH AMERICA: RECOMBINANT PROTEINS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.2.1 NORTH AMERICA: RECESSION IMPACT
    • 10.2.2 US
      • 10.2.2.1 Rising investments in life sciences research to drive market
    • TABLE 227 US: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 228 US: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 229 US: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 230 US: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 231 US: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 232 US: RECOMBINANT PROTEINS MARKET, BY HOST CELL, 2021-2028 (USD MILLION)
    • TABLE 233 US: RECOMBINANT PROTEINS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.2.3 CANADA
      • 10.2.3.1 High incidence of cancer and favorable healthcare investments to drive market
    • TABLE 234 CANADA: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 235 CANADA: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 236 CANADA: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 237 CANADA: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 238 CANADA: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 239 CANADA: RECOMBINANT PROTEINS MARKET, BY HOST CELL, 2021-2028 (USD MILLION)
    • TABLE 240 CANADA: RECOMBINANT PROTEINS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 10.3 EUROPE
    • TABLE 241 EUROPE: RECOMBINANT PROTEINS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 242 EUROPE: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 243 EUROPE: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 244 EUROPE: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 245 EUROPE: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 246 EUROPE: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 247 EUROPE: RECOMBINANT PROTEINS MARKET, BY HOST CELL, 2021-2028 (USD MILLION)
    • TABLE 248 EUROPE: RECOMBINANT PROTEINS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.3.1 EUROPE: RECESSION IMPACT
    • 10.3.2 GERMANY
      • 10.3.2.1 Growing focus on biotech clusters to drive market
    • TABLE 249 GERMANY: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 250 GERMANY: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 251 GERMANY: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 252 GERMANY: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 253 GERMANY: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 254 GERMANY: RECOMBINANT PROTEINS MARKET, BY HOST CELL, 2021-2028 (USD MILLION)
    • TABLE 255 GERMANY: RECOMBINANT PROTEINS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.3.3 UK
      • 10.3.3.1 Rising demand for biologics and biosimilars to propel market
    • TABLE 256 UK: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 257 UK: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 258 UK: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 259 UK: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 260 UK: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 261 UK: RECOMBINANT PROTEINS MARKET, BY HOST CELL, 2021-2028 (USD MILLION)
    • TABLE 262 UK: RECOMBINANT PROTEINS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.3.4 FRANCE
      • 10.3.4.1 Rising establishment of biopharmaceutical production facilities to boost demand
    • TABLE 263 FRANCE: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 264 FRANCE: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 265 FRANCE: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 266 FRANCE: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 267 FRANCE: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 268 FRANCE: RECOMBINANT PROTEINS MARKET, BY HOST CELL, 2021-2028 (USD MILLION)
    • TABLE 269 FRANCE: RECOMBINANT PROTEINS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.3.5 ITALY
      • 10.3.5.1 Growth in proteomics and genomics research to drive market
    • TABLE 270 ITALY: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 271 ITALY: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 272 ITALY: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 273 ITALY: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 274 ITALY: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 275 ITALY: RECOMBINANT PROTEINS MARKET, BY HOST CELL, 2021-2028 (USD MILLION)
    • TABLE 276 ITALY: RECOMBINANT PROTEINS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.3.6 SPAIN
      • 10.3.6.1 Rising establishment of pharmaceutical production facilities to drive market
    • TABLE 277 SPAIN: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 278 SPAIN: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 279 SPAIN: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 280 SPAIN: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 281 SPAIN: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 282 SPAIN: RECOMBINANT PROTEINS MARKET, BY HOST CELL, 2021-2028 (USD MILLION)
    • TABLE 283 SPAIN: RECOMBINANT PROTEINS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.3.7 REST OF EUROPE
    • TABLE 284 REST OF EUROPE: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 285 REST OF EUROPE: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 286 REST OF EUROPE: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 287 REST OF EUROPE: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 288 REST OF EUROPE: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 289 REST OF EUROPE: RECOMBINANT PROTEINS MARKET, BY HOST CELL, 2021-2028 (USD MILLION)
    • TABLE 290 REST OF EUROPE: RECOMBINANT PROTEINS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 10.4 ASIA PACIFIC
    • FIGURE 31 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET SNAPSHOT
    • TABLE 291 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 292 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 293 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 294 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 295 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR RESEARCH APPLICATION, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 296 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT APPLICATION, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 297 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET, BY HOST CELL, 2021-2028 (USD MILLION)
    • TABLE 298 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.4.1 ASIA PACIFIC: RECESSION IMPACT
    • 10.4.2 CHINA
      • 10.4.2.1 Expansion of R&D infrastructure to support market growth
    • TABLE 299 CHINA: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 300 CHINA: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 301 CHINA: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 302 CHINA: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 303 CHINA: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 304 CHINA: RECOMBINANT PROTEINS MARKET, BY HOST CELL, 2021-2028 (USD MILLION)
    • TABLE 305 CHINA: RECOMBINANT PROTEINS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.4.3 JAPAN
      • 10.4.3.1 Growth in pharmaceutical industry to propel market
    • TABLE 306 JAPAN: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 307 JAPAN: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 308 JAPAN: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 309 JAPAN: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 310 JAPAN: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 311 JAPAN: RECOMBINANT PROTEINS MARKET, BY HOST CELL, 2021-2028 (USD MILLION)
    • TABLE 312 JAPAN: RECOMBINANT PROTEINS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.4.4 INDIA
      • 10.4.4.1 Rising demand for drug discovery & development to propel market
    • TABLE 313 INDIA: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 314 INDIA: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 315 INDIA: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 316 INDIA: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 317 INDIA: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 318 INDIA: RECOMBINANT PROTEINS MARKET, BY HOST CELL, 2021-2028 (USD MILLION)
    • TABLE 319 INDIA: RECOMBINANT PROTEINS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.4.5 SOUTH KOREA
      • 10.4.5.1 Rising incidence of infectious diseases to drive market
    • TABLE 320 SOUTH KOREA: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 321 SOUTH KOREA: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 322 SOUTH KOREA: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 323 SOUTH KOREA: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 324 SOUTH KOREA: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 325 SOUTH KOREA: RECOMBINANT PROTEINS MARKET, BY HOST CELL, 2021-2028 (USD MILLION)
    • TABLE 326 SOUTH KOREA: RECOMBINANT PROTEINS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.4.6 REST OF ASIA PACIFIC
    • TABLE 327 REST OF ASIA PACIFIC: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 328 REST OF ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 329 REST OF ASIA PACIFIC: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 330 REST OF ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 331 REST OF ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 332 REST OF ASIA PACIFIC: RECOMBINANT PROTEINS MARKET, BY HOST CELL, 2021-2028 (USD MILLION)
    • TABLE 333 REST OF ASIA PACIFIC: RECOMBINANT PROTEINS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 10.5 LATIN AMERICA
    • TABLE 334 LATIN AMERICA: RECOMBINANT PROTEINS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 335 LATIN AMERICA: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 336 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 337 LATIN AMERICA: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 338 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 339 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 340 LATIN AMERICA: RECOMBINANT PROTEINS MARKET, BY HOST CELL, 2021-2028 (USD MILLION)
    • TABLE 341 LATIN AMERICA: RECOMBINANT PROTEINS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.5.1 LATIN AMERICA: RECESSION IMPACT
    • 10.5.2 BRAZIL
      • 10.5.2.1 Rising incidence of chronic diseases to drive market
    • TABLE 342 BRAZIL: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 343 BRAZIL: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 344 BRAZIL: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 345 BRAZIL: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 346 BRAZIL: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 347 BRAZIL: RECOMBINANT PROTEINS MARKET, BY HOST CELL, 2021-2028 (USD MILLION)
    • TABLE 348 BRAZIL: RECOMBINANT PROTEINS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.5.3 REST OF LATIN AMERICA
    • TABLE 349 REST OF LATIN AMERICA: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 350 REST OF LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 351 REST OF LATIN AMERICA: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 352 REST OF LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 353 REST OF LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 354 REST OF LATIN AMERICA: RECOMBINANT PROTEINS MARKET, BY HOST CELL, 2021-2028 (USD MILLION)
    • TABLE 355 REST OF LATIN AMERICA: RECOMBINANT PROTEINS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 10.6 MIDDLE EAST
    • TABLE 356 MIDDLE EAST: RECOMBINANT PROTEINS MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 357 MIDDLE EAST: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 358 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 359 MIDDLE EAST: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 360 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 361 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 362 MIDDLE EAST: RECOMBINANT PROTEINS MARKET, BY HOST CELL, 2021-2028 (USD MILLION)
    • TABLE 363 MIDDLE EAST: RECOMBINANT PROTEINS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.6.1 MIDDLE EAST: RECESSION IMPACT
    • 10.6.2 GCC COUNTRIES
      • 10.6.2.1 Rising government investments in healthcare to support market growth
    • TABLE 364 GCC COUNTRIES: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 365 GCC COUNTRIES: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 366 GCC COUNTRIES: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 367 GCC COUNTRIES: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 368 GCC COUNTRIES: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 369 GCC COUNTRIES: RECOMBINANT PROTEINS MARKET, BY HOST CELL, 2021-2028 (USD MILLION)
    • TABLE 370 GCC COUNTRIES: RECOMBINANT PROTEINS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.6.3 REST OF THE MIDDLE EAST
    • TABLE 371 REST OF THE MIDDLE EAST: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 372 REST OF THE MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 373 REST OF THE MIDDLE EAST: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 374 REST OF THE MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 375 REST OF THE MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 376 REST OF THE MIDDLE EAST: RECOMBINANT PROTEINS MARKET, BY HOST CELL, 2021-2028 (USD MILLION)
    • TABLE 377 REST OF THE MIDDLE EAST: RECOMBINANT PROTEINS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 10.7 AFRICA
    • 10.7.1 IMPROVEMENTS IN HEALTHCARE INFRASTRUCTURE TO SUPPORT MARKET GROWTH
    • TABLE 378 AFRICA: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 379 AFRICA: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 380 AFRICA: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 381 AFRICA: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 382 AFRICA: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 383 AFRICA: RECOMBINANT PROTEINS MARKET, BY HOST CELL, 2021-2028 (USD MILLION)
    • TABLE 384 AFRICA: RECOMBINANT PROTEINS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.7.2 AFRICA: RECESSION IMPACT

11 COMPETITIVE LANDSCAPE

  • 11.1 INTRODUCTION
  • 11.2 KEY PLAYER STRATEGIES
    • FIGURE 32 STRATEGIES ADOPTED BY KEY PLAYERS/RIGHT TO WIN
  • 11.3 REVENUE SHARE ANALYSIS
    • FIGURE 33 REVENUE SHARE ANALYSIS OF KEY PLAYERS (2020-2022)
  • 11.4 MARKET SHARE ANALYSIS
    • FIGURE 34 RECOMBINANT PROTEINS MARKET: MARKET SHARE ANALYSIS OF KEY PLAYERS (2022)
    • TABLE 385 RECOMBINANT PROTEINS MARKET: INTENSITY OF COMPETITIVE RIVALRY
  • 11.5 COMPANY EVALUATION MATRIX
    • FIGURE 35 RECOMBINANT PROTEINS MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS (2022)
    • 11.5.1 STARS
    • 11.5.2 EMERGING LEADERS
    • 11.5.3 PERVASIVE PLAYERS
    • 11.5.4 PARTICIPANTS
    • 11.5.5 COMPETITIVE BENCHMARKING
      • 11.5.5.1 Product footprint (15 companies)
    • TABLE 386 RECOMBINANT PROTEINS MARKET: COMPANY PRODUCT FOOTPRINT
      • 11.5.5.2 Regional footprint
    • TABLE 387 RECOMBINANT PROTEINS MARKET: REGIONAL FOOTPRINT ANALYSIS
  • 11.6 START-UP/SME EVALUATION MATRIX
    • 11.6.1 PROGRESSIVE COMPANIES
    • 11.6.2 STARTING BLOCKS
    • 11.6.3 RESPONSIVE COMPANIES
    • 11.6.4 DYNAMIC COMPANIES
    • FIGURE 36 RECOMBINANT PROTEINS MARKET: COMPANY EVALUATION MATRIX FOR START-UPS/SMES (2022)
    • 11.6.5 COMPETITIVE BENCHMARKING OF START-UPS/SMES
    • TABLE 388 RECOMBINANT PROTEINS MARKET: PRODUCT FOOTPRINT
    • TABLE 389 RECOMBINANT PROTEINS MARKET: REGIONAL FOOTPRINT
  • 11.7 COMPETITIVE SCENARIO
    • 11.7.1 PRODUCT LAUNCHES & APPROVALS
    • TABLE 390 RECOMBINANT PROTEINS MARKET: PRODUCT LAUNCHES & APPROVALS, (JANUARY 2021-SEPTEMBER 2023)
    • 11.7.2 DEALS
    • TABLE 391 RECOMBINANT PROTEINS MARKET: DEALS (JANUARY 2021-SEPTEMBER 2023)
    • 11.7.3 OTHER DEVELOPMENTS
    • TABLE 392 RECOMBINANT PROTEINS MARKET: OTHER DEVELOPMENTS (JANUARY 2021-SEPTEMBER 2023)

12 COMPANY PROFILES

  • (Business overview, Products offered, Recent developments & MnM View)**
  • 12.1 KEY PLAYERS
    • 12.1.1 BIO-TECHNE
    • TABLE 393 BIO-TECHNE: BUSINESS OVERVIEW
    • FIGURE 37 BIO-TECHNE: COMPANY SNAPSHOT (2022)
    • TABLE 394 BIO-TECHNE: PRODUCTS OFFERED
    • TABLE 395 BIO-TECHNE: DEALS
    • TABLE 396 BIO-TECHNE: OTHER DEVELOPMENTS
    • 12.1.2 THERMO FISHER SCIENTIFIC INC.
    • TABLE 397 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW
    • FIGURE 38 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022)
    • TABLE 398 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED
    • TABLE 399 THERMO FISHER SCIENTIFIC INC: DEALS
    • 12.1.3 MERCK KGAA
    • TABLE 400 MERCK KGAA: BUSINESS OVERVIEW
    • FIGURE 39 MERCK KGAA: COMPANY SNAPSHOT (2022)
    • TABLE 401 MERCK KGAA: PRODUCTS OFFERED
    • TABLE 402 MERCK KGAA: DEALS
    • TABLE 403 MERCK KGAA: OTHER DEVELOPMENTS
    • 12.1.4 ABCAM PLC
    • TABLE 404 ABCAM PLC: BUSINESS OVERVIEW
    • FIGURE 40 ABCAM PLC: COMPANY SNAPSHOT (2022)
    • TABLE 405 ABCAM PLC: PRODUCTS OFFERED
    • TABLE 406 ABCAM PLC: DEALS
    • TABLE 407 ABCAM PLC: OTHER DEVELOPMENTS
    • 12.1.5 ABNOVA CORPORATION
    • TABLE 408 ABNOVA CORPORATION: BUSINESS OVERVIEW
    • TABLE 409 ABNOVA CORPORATION: PRODUCTS OFFERED
    • 12.1.6 BIOLEGEND, INC
    • TABLE 410 BIOLEGEND INC: BUSINESS OVERVIEW
    • TABLE 411 BIOLEGEND INC: PRODUCTS OFFERED
    • 12.1.7 BIO-RAD LABORATORIES, INC.
    • TABLE 412 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW
    • FIGURE 41 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2022)
    • TABLE 413 BIO-RAD LABORATORIES, INC.: PRODUCTS OFFERED
    • 12.1.8 BPS BIOSCIENCE, INC.
    • TABLE 414 BPS BIOSCIENCE, INC.: BUSINESS OVERVIEW
    • TABLE 415 BPS BIOSCIENCE, INC.: PRODUCTS OFFERED
    • 12.1.9 ENZO LIFE SCIENCES, INC. (SUBSIDIARY OF ENZO BIOCHEM, INC.)
    • TABLE 416 ENZO BIOCHEM, INC.: BUSINESS OVERVIEW
    • FIGURE 42 ENZO BIOCHEM, INC.: COMPANY SNAPSHOT (2022)
    • TABLE 417 ENZO BIOCHEM, INC.: PRODUCTS OFFERED
    • TABLE 418 ENZO BIOCHEM, INC.: OTHER DEVELOPMENTS
    • 12.1.10 GENSCRIPT
    • TABLE 419 GENSCRIPT: BUSINESS OVERVIEW
    • FIGURE 43 GENSCRIPT: COMPANY SNAPSHOT (2022)
    • TABLE 420 GENSCRIPT: PRODUCTS OFFERED
    • 12.1.11 MILTENYI BIOTEC B.V. & CO. KG
    • TABLE 421 MILTENYI BIOTEC B.V. & CO. KG: BUSINESS OVERVIEW
    • TABLE 422 MILTENYI BIOTEC B.V. & CO. KG: PRODUCTS OFFERED
    • TABLE 423 MILTENYI BIOTEC B.V. & CO. KG: PRODUCT LAUNCHES
    • 12.1.12 PROTEINTECH GROUP, INC.
    • TABLE 424 PROTEINTECH GROUP, INC.: BUSINESS OVERVIEW
    • TABLE 425 PROTEINTECH GROUP, INC.: PRODUCTS OFFERED
    • TABLE 426 PROTEINTECH GROUP, INC.: DEALS
    • TABLE 427 PROTEINTECH GROUP, INC.: OTHER DEVELOPMENTS
    • 12.1.13 SINO BIOLOGICAL, INC.
    • TABLE 428 SINO BIOLOGICAL, INC.: BUSINESS OVERVIEW
    • TABLE 429 SINO BIOLOGICAL, INC.: PRODUCTS OFFERED
    • TABLE 430 SINO BIOLOGICAL, INC.: PRODUCT LAUNCHES
    • TABLE 431 SINO BIOLOGICAL, INC.: DEALS
    • TABLE 432 SINO BIOLOGICAL, INC.: OTHER DEVELOPMENTS
  • *Details on Business overview, Products offered, Recent developments & MnM View might not be captured in case of unlisted companies.
  • 12.2 OTHER PLAYERS
    • 12.2.1 ACROBIOSYSTEMS GROUP
    • 12.2.2 AVIVA SYSTEMS BIOLOGY CORPORATION
    • 12.2.3 SARTORIUS CELLGENIX GMBH
    • 12.2.4 ICOSAGEN
    • 12.2.5 NEUROMICS
    • 12.2.6 PROSPEC-TANY TECHNOGENE LTD.
    • 12.2.7 PROTEOGENIX S.A.S
    • 12.2.8 RAYBIOTECH, INC.
    • 12.2.9 LAURUS BIO
    • 12.2.10 STEMCELL TECHNOLOGIES
    • 12.2.11 STRESSMARQ BIOSCIENCES INC.
    • 12.2.12 UNITED STATES BIOLOGICAL

13 APPENDIX

  • 13.1 DISCUSSION GUIDE
  • 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.3 CUSTOMIZATION OPTIONS
  • 13.4 RELATED REPORTS
  • 13.5 AUTHOR DETAILS